California Passes Biosimilars Bill to Promote Access to Biologic Medicines

  • Contact: George Goodno
  • Phone: 202-962-6660
  • Email:
  • Recommend
  • Tweet
  • Print
  • Email

Washington, D.C. (September 5, 2013) – Jim Greenwood, President and CEO of the Biotechnology Industry Organization (BIO), today issued the following statement on the California Senate's passage of Senate Bill 598:

"I commend California's Assembly and Senate for overwhelmingly passing legislation that creates a pathway for the substitution of interchangeable biologic medicines.

"As the policies outlined in Senate Bill 598 align with BIO’s principles on biologic substitution, BIO supports this important legislation and encourages Governor Brown to sign the bill when it reaches his desk.

"BIO is pleased that the California Legislature passed this legislation and continues to put patients first."


About BIO
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.